---
marp: true
theme: default
paginate: true
title: Medicinal Chemistry of Benzodiazepines
author: PHA 548 â€“ Pharmacology & Medicinal Chemistry
---

# ðŸ§¬ Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics

Foyeâ€™s Principles of Medicinal Chemistry, 8th Ed.  
75â€“90 min | PHA 548

---

## ðŸŽ¯ Learning Objectives

- Explain benzodiazepine MOA at the GABAA Î±â€“Î³ interface  
- Analyze SAR impacts on affinity, potency, and selectivity  
- Predict PK outcomes from structure  
- Evaluate design evolution through remimazolam  

---

## ðŸ§  GABAA Architecture & MOA

- Pentameric Clâ» channel (2Î± + 2Î² + 1Î³)
- **BZD binding = Î±â€“Î³ interface**
- â†‘ frequency of Clâ» channel openings  
- **GABA required**

---

## Subtype Selectivity

| Subunit | Effect |
|--------|--------|
| Î±1 | Sedation, amnesia |
| Î±2/Î±3 | Anxiolysis, muscle relaxation |
| Î±5 | Cognitive impairment |

---

## ðŸ§± Required Pharmacophore

**5-phenyl-1,4-benzodiazepine-2-one**

- C7: Electronegative substituent  
- C5: Phenyl (planar)  
- N1-C2: Carbonyl (H-bond anchor)

---

## ðŸ”¬ Structureâ€“Activity Relationships (SAR)

| Site | Rule | Effect |
|------|------|-------|
| C7 Halogen | Essential | â†‘ Affinity |
| C5 Phenyl | Required | Ï€-stacking |
| o-Halogenation | â†‘ CNS entry | â†‘ duration |
| p-substitution | **Inactive** | Steric clash |
| C3-OH | â†‘ conjugation | Shorter duration |
| Triazolo fusion | Shielding | â†‘ potency |
| Ester linker | Esterases | **Ultra-short** |

---

## ðŸ§ª SAR â†’ PK Relationship

**Medicinal chemistry theme**  
> Replace **oxidative liabilities** with **hydrolytic liabilities**

---

## PK Differences from SAR

| Drug | SAR Feature | PK Effect |
|------|-------------|----------|
| Flurazepam | N-alkyl | Long-acting |
| Quazepam | Lipophilic | Accumulation |
| Estazolam | Triazole | Intermediate |
| Triazolam | Compact | Short-acting |
| Temazepam | C3-OH | Rapid clearance |
| Remimazolam | Ester | **Ultra-short** |

---

## ðŸ§© Active Learning: SAR Challenge

Predict outcomes:

- Remove 7-Cl  
- Add para bulky group  
- Add C3-OH  
- Add triazole  
- Add ester (Remimazolam-like)

Discuss with your partner!

---

## âœ” Key Takeaways

| Change | Result |
|-------|--------|
| â†‘ Lipophilicity | â†‘ CNS entry & duration |
| â†‘ Oxidation sites | Active metabolite buildup |
| â†‘ Conjugation | Faster elimination |
| Shielding | Predictable PK |
| Ester hydrolysis | Procedural control |

---

# Questions?

